- im Depot von BB Biotech vertreten
www.technologyreview.com/s/608749/...-editing-without-crispr/
|
www.technologyreview.com/s/608749/...-editing-without-crispr/
28 Beiträge ausgeblendet. |
|
Zahlen für Q2/21
Homology expects cash resources to fund operations into the first quarter of 2023
- On Track to Report Initial Results from Phase 2 pheNIX Gene Therapy Trial for Adults with PKU in 2021
- Plans to Initiate First-Ever Gene Editing Trial for PKU with HMI-103 This Year
- Expects to Commence Clinical Trial with HMI-203 In Vivo Gene Therapy Candidate for MPS II by Year End
investors.homologymedicines.com/...ter-2021-financial-results
Zahlen für Q3/21
Homology continues to expect cash resources to fund operations into the first quarter of 2023.
investors.homologymedicines.com/...ter-2021-financial-results
Deal mit Oxford Biomedica
www.fiercebiotech.com/biotech/...-to-fund-gene-therapy-trials
FDA verhängt einen klinischen Stop für HMI-102
investors.homologymedicines.com/...-phenix-gene-therapy-trial
Zahlen für Q4/21
"Based on current projections, Homology expects current cash resources, including the $130.0 million received from Oxford Biomedica in March 2022, to fund operations into the second half of 2024"
investors.homologymedicines.com/...quarter-and-full-year-2021
Ich denke, dass das Chancen-Risiko-Verhältnis hier mindestens ausgelichen ist. Derzeit liegt der Cashbestand (~285 Mio. $) deutlich über der MK, zudem ist FIXX bis ins Jahr 2024 durchfinanziert.
FDA hebt den klinischen Stop der Gentherapiestudie HMI-102 (PKU) auf
www.homologymedicines.com/news-story/...therapy-trial-for-pku
Zahlen für Q3/22
- fund operations into the fourth quarter of 2024
investors.homologymedicines.com/...ter-2022-financial-results
Zahlen für Q4/22
- expects current cash resources to fund operations into the fourth quarter of 2024
investors.homologymedicines.com/...quarter-and-full-year-2022
- On Track to Provide Initial Clinical Data from Gene Editing Trial for PKU Mid-Year
Mitte des Jahres könnte Juli oder August bedeuten
Zahlen für Q1/23
- fund operations into the fourth quarter of 2024
investors.homologymedicines.com/...quarter-and-full-year-2022
prüft strategische Alternativen
investors.homologymedicines.com/...evaluate-strategic-options
geplantes Merger mit Q32
investors.homologymedicines.com/...-announce-merger-agreement
ir.q32bio.com/news-releases/...-merger-homology-medicines-and
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
53 | FIXX 17,69$ | Vassago | Vassago | 07.04.24 16:30 |